deferiprone has been researched along with Rhabdomyolysis in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Herein, the efficacy of free deferiprone (DFP) and DFP-loaded starch/polyethylene glycol/polyacrylic acid (St/PEG/PAAc) nanogel [Nano-DFP] in modulating the biochemical changes induced by glycerol model of rhabdomyolysis (RBD) in male rats was investigated." | 7.96 | Effectiveness of deferiprone-loaded nanocarrier in experimentally induced rhabdomyolysis: A dose-comparison study. ( Deghiedy, NM; El-Ghazaly, MA; El-Hazek, RM; El-Sabbagh, WA; Rashed, ER; Rashed, RR, 2020) |
| "Herein, the efficacy of free deferiprone (DFP) and DFP-loaded starch/polyethylene glycol/polyacrylic acid (St/PEG/PAAc) nanogel [Nano-DFP] in modulating the biochemical changes induced by glycerol model of rhabdomyolysis (RBD) in male rats was investigated." | 3.96 | Effectiveness of deferiprone-loaded nanocarrier in experimentally induced rhabdomyolysis: A dose-comparison study. ( Deghiedy, NM; El-Ghazaly, MA; El-Hazek, RM; El-Sabbagh, WA; Rashed, ER; Rashed, RR, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rashed, RR | 1 |
| Deghiedy, NM | 1 |
| El-Hazek, RM | 1 |
| El-Sabbagh, WA | 1 |
| Rashed, ER | 1 |
| El-Ghazaly, MA | 1 |
1 other study available for deferiprone and Rhabdomyolysis
| Article | Year |
|---|---|
Effectiveness of deferiprone-loaded nanocarrier in experimentally induced rhabdomyolysis: A dose-comparison study.
Topics: Animals; Deferiprone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Iron | 2020 |